Evidence map›Paper›PMID 37783940›Full record

ArticleNature chemical biology2023

Assigning functionality to cysteines by base editing of cancer dependency genes.

Haoxin Li, Tiantai Ma, Jarrett R Remsberg, Sang Joon Won, Kristen E DeMeester, Evert Njomen, Daisuke Ogasawara, Kevin T Zhao, Tony P Huang, Bingwen Lu and 6 more

Open access · greenAbstract read
In one paragraph

Article in Nature chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Haoxin LiDepartment of Chemistry, Scripps Research, La Jolla, CA, USA. haoxinli@scripps.edu.
Tiantai MaDepartment of Molecular Biology, School of Biological Sciences, University of California San Diego, La Jolla, CA, USA.
Jarrett R RemsbergDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.ORCID 0000-0002-5234-0168
Sang Joon WonDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.ORCID 0000-0002-8148-7652
Kristen E DeMeesterDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.
Evert NjomenDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.
Daisuke OgasawaraDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.ORCID 0000-0002-2178-4698
Kevin T ZhaoMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0003-3440-2094
Tony P HuangMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Bingwen LuVividion Therapeutics, San Diego, CA, USA.
Gabriel M SimonVividion Therapeutics, San Diego, CA, USA.
Bruno MelilloDepartment of Chemistry, Scripps Research, La Jolla, CA, USA.ORCID 0000-0002-9708-5287
Stuart L SchreiberDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.ORCID 0000-0003-1922-7558
Jens Lykke-AndersenDepartment of Molecular Biology, School of Biological Sciences, University of California San Diego, La Jolla, CA, USA.
David R LiuMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-9943-7557
Benjamin F CravattDepartment of Chemistry, Scripps Research, La Jolla, CA, USA. cravatt@scripps.edu.ORCID 0000-0001-5330-3492
Scripps Institution of Oceanography · USBroad Institute · USScripps Research Institute · USUniversity of California San Diego · USVividion Therapeutics (United States) · US

Funding

Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human DiseaseRM1HG009490 · NHGRI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI Brittany S. Adamson, Martin Joseph Ankrah Aryee · 2017 to 2026
$22.7M
Chemical Proteomic Platforms for Radically Expanding Cancer DruggabilityR35CA231991 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BENJAMIN F CRAVATT · 2018 to 2026
$9.5M
Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel TherapeuticsR35GM118062 · NIGMS · HARVARD UNIVERSITY · PI LIU, DAVID R · 2016 to 2025
$6.4M
Mechanisms of human RNA turnover and quality controlR35GM118069 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LYKKE-ANDERSEN, JENS · 2016 to 2025
$5.1M
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.R01CA238249 · NCI · STANFORD UNIVERSITY · PI CRAVATT, BENJAMIN F, MISCHEL, PAUL S · 2021 to 2025
$3.3M
Expanding the Scope of Base EditingU01AI142756 · NIAID · BROAD INSTITUTE, INC. · PI LIU, DAVID R · 2018 to 2022
$2.1M
NCI NIH HHS R01 CA238249NCI NIH HHS R35 CA231991NHGRI NIH HHS RM1 HG009490NIAID NIH HHS U01 AI142756NIGMS NIH HHS R35 GM118062NIGMS NIH HHS R35 GM118069
6 · The paper itself

Abstract

Covalent chemistry represents an attractive strategy for expanding the ligandability of the proteome, and chemical proteomics has revealed numerous electrophile-reactive cysteines on diverse human proteins. Determining which of these covalent binding events affect protein function, however, remains challenging. Here we describe a base-editing strategy to infer the functionality of cysteines by quantifying the impact of their missense mutation on cancer cell proliferation. The resulting atlas, which covers more than 13,800 cysteines on more than 1,750 cancer dependency proteins, confirms the essentiality of cysteines targeted by covalent drugs and, when integrated with chemical proteomic data, identifies essential, ligandable cysteines in more than 160 cancer dependency proteins. We further show that a stereoselective and site-specific ligand targeting an essential cysteine in TOE1 inhibits the nuclease activity of this protein through an apparent allosteric mechanism. Our findings thus describe a versatile method and valuable resource to prioritize the pursuit of small-molecule probes with high function-perturbing potential.

Indexed as

CysteineNeoplasmsGene EditingHumansNuclear ProteinsProteomeProteomicsCysteineNuclear ProteinsProteomeTOE1 protein, human

Identifiers

PMID37783940
PMCPMC10698195
OpenAlexW4387252290

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.